Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Forigerimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.66 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.66 |
| ▸ | CALCR | P30988 | 4/20 | 0.64 |
| ▸ | F2 | P00734 | 4/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.57 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.57 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 1/20 | 0.57 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Forigerimod SCHEMBL29382270 | 0.99 | CRHR1 (0.67) | CRHR1CRHR2CALCRF2C5AR1 | |
| SCHEMBL21318133 | 0.92 | CALCR (0.62) | CRHR1CRHR2CALCRC5AR1GLP1R | |
| SCHEMBL29767110 | 0.85 | CALCR (0.82) | CRHR1CRHR2CALCRF2HCRTR1 | |
| SCHEMBL18888624 | 0.85 | C5AR1 (0.60) | CRHR1CRHR2CALCRC5AR1GLP1R | |
| SCHEMBL31182543 | 0.84 | CALCR (0.79) | CRHR1CRHR2CALCRF2HCRTR1 | |
| SCHEMBL29379306 | 0.84 | F2 (0.78) | CRHR1CRHR2CALCRF2C5AR1 | |
| SCHEMBL31182553 | 0.84 | CALCR (0.79) | CRHR1CRHR2CALCRF2HCRTR1 | |
| SCHEMBL30932076 | 0.83 | CALCR (0.82) | CRHR1CRHR2CALCRF2HCRTR1 | |
| SCHEMBL30261994 | 0.83 | C5AR1 (0.65) | CALCRC5AR1GLP1R | |
| SCHEMBL30712915 | 0.83 | CALCR (0.69) | CRHR1CRHR2CALCRF2C5AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250367267-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | LIRUM THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-4547265-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | Lirum Therapeutics, Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| CN-119698288-A | Treatment of autoimmune diseases with insulin-like growth factor 1 receptor ligands conjugated to agents | 利鲁姆治疗公司 | 2025-03-25 | — | — | CN | claimed |
| WO-2024212964-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING TUMORS, AND PHARMACEUTICAL COMBINATION AND USE THEREOF | 中国科学院分子细胞科学卓越创新中心 | 2024-10-17 | — | — | WO | claimed |
| CN-118662640-A | Pharmaceutical composition for preventing and/or treating tumor, pharmaceutical composition and application thereof | 中国科学院分子细胞科学卓越创新中心 | 2024-09-20 | — | — | CN | claimed |
| WO-2024176194-A1 | METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR mRNA VACCINE ADMINISTRATION | PKZ, LLC (US) | 2024-08-29 | — | — | WO | claimed |
| US-20240285655-A1 | METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR MRNA VACCINE ADMINISTRATION | PKZ, LLC | 2024-08-29 | — | — | US | claimed |
| WO-2024006940-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | LIRUM THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | claimed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-12618031-B2 | Delivery devices | THE METHODIST HOSPITAL SYSTEM (US) | 2026-05-05 | — | — | US | disclosed |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | CTXT PTY LTD (AU) | 2026-05-05 | — | — | US | disclosed |
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | TWELVE THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20250367267-A1 | TREATING AUTOIMMUNE DISEASES WITH INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR LIGAND CONJUGATED TO AN AGENT | LIRUM THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250339514-A1 | SINGLE-AND MULTI-EPITOPE PEPTIDE AND MRNA VACCINES TO GENERATE TOLEROGENIC EFFECTS FOR ALLERGIC AND AUTOIMMUNE DISEASE BY TARGETING LIVER SINUSOIDAL ENDOTHELIAL CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-06 | — | — | US | disclosed |
| EP-3969438-A1 | OXOACRIDINYL ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3969452-A1 | BENZO[B][1,8]NAPHTHYRIDINE ACETIC ACID DERIVATIVES AND METHODS OF USE | Stingthera, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| EP-3971211-A1 | HIDE1 COMPOSITIONS AND METHODS | Compugen Ltd. (IL) | 2022-03-23 | — | — | EP | disclosed |
| CN-114206880-A | Benzothiophene, thienopyridine, and thienopyrimidine derivatives for modulation of STING | CTXT私人有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-114206882-A | Benzothiophene, thienopyridine, and thienopyrimidine derivatives for modulation of STING | CTXT私人有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3964507-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Infinity Pharmaceuticals, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049087-A1 | SOLID FORMS OF ISOQUINOLINONES, AND PROCESS OF MAKING, COMPOSITION COMPRISING, AND METHODS OF USING THE SAME | PRKCB, PRKCD, PRKCA | CRHR1 4188/4885CRHR2 4278/4885CALCR 2341/4885 |
| US-12618031-B2 | Delivery devices | VEGFA, PGF, CD47 | CRHR1 243/4885CRHR2 294/4885CALCR 843/4885 |
| US-20240285655-A1 | METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR MRNA VACCINE ADMINISTRATION | IL2, IL1B, IFNG | CRHR1 318/4885CRHR2 185/4885CALCR 55/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | CRHR1 569/4885CRHR2 959/4885CALCR 363/4885 |
| US-12617780-B2 | Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting | STING1, CGAS, IRF3 | CRHR1 1346/4885CRHR2 1402/4885CALCR 634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.